More importantly, STAT3 has been found as an initiator and master regulator of brain tumor mesenchymal transformation [65]; MSH6 mutations have reported to affect treatment response in Glioblastoma [66]; and Myc has been found separately associated to glioma/glioblastoma [67][68] and mesenchymal transition of epithelial cells [69]. Here, STAT3 is linked to central nervous system cancer.